Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome Data Readouts Expected from Cohort 1 in 3Q 2025 and Cohort 2 in 4Q 2025 NEW HAVEN, Conn. / Jun 12, 2025 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative... Read More

On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 NEW HAVEN, Conn. / May 08, 2025 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative... Read More

NEW HAVEN, Conn. / Apr 29, 2025 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025 at 12:00... Read More

RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025 NEW HAVEN, Conn. / Apr 08, 2025 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare... Read More

Key Data Readouts from Sentinel Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 and 3Q 2025 Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 $65.5 Million in Cash, Cash Equivalents, and Marketable Securities as of December 31, 2024 Provides Runway into 2H 2026 NEW HAVEN, Conn. / Mar 13, 2025 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a... Read More

NEW HAVEN, Conn. / Feb 25, 2025 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will present a corporate overview at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at... Read More

Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 NEW HAVEN, Conn. / Feb 11, 2025 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the first participant has been dosed in the Phase 2 trial investigating RLYB212 in pregnant women... Read More

Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 REV102, an ENPP1 Inhibitor for the Treatment of Hypophosphatasia, to Enter IND-Enabling Studies in 2025 NEW HAVEN, Conn. / Jan 10, 2025 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company... Read More

NEW HAVEN, Conn. / Dec 10, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66 th American Society of Hematology (ASH) Annual... Read More

New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study Manufacturing Process Enhancements Expected to Further Improve RLYB116 Tolerability Webcast Today at 8:30 AM Eastern Time NEW HAVEN, Conn. / Dec 02, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into... Read More

Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial NEW HAVEN, Conn. / Nov 27, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, “Informing Pregnancy Dose via Target-Mediated Drug... Read More

NEW HAVEN, Conn. / Nov 26, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024 at 12:30... Read More

Webcast to be held on Monday, December 2, 2024 at 8:30 AM Eastern Time NEW HAVEN, Conn. / Nov 25, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly,... Read More

Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT NEW HAVEN, Conn. / Nov 21, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in... Read More

CTA Approvals Received for RLYB212 Phase 2 Clinical Trial; On Track to Initiate Screening in 4Q 2024 $75.1 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2024 Provides Runway into Mid-2026 NEW HAVEN, Conn. / Nov 07, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with... Read More

First Ever Trial in Pregnant Women at Higher Risk of Alloimmunization and FNAIT Screening in the Phase 2 Clinical Trial On Track to Initiate in 4Q 2024 NEW HAVEN, Conn. / Oct 29, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the approval of its... Read More

NEW HAVEN, Conn. / Sep 30, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data demonstrating ENPP1 inhibition as a therapeutic approach for the treatment of patients with hypophosphatasia (HPP) was presented at the American Society for... Read More

Results Indicate that FNAIT Risk is More Prevalent Than Previously Estimated NEW HAVEN, Conn. / Sep 23, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse... Read More

NEW HAVEN, Conn. / Sep 10, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia... Read More

NEW HAVEN, Conn. / Sep 09, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that Fierce Life Sciences and Fierce Healthcare has named Rallybio an Innovation Honoree as part of the 2024 Fierce 50 list. The Fierce 50 showcases 50 individuals and companies... Read More

Study Demonstrates that RLYB212 Rapidly Clears HPA-1a Positive Platelets, an Essential Step in Preventing Alloimmunization and FNAIT Rallybio On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk for FNAIT in 4Q 2024 NEW HAVEN, Conn. / Aug 29, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into... Read More

NEW HAVEN, Conn. / Aug 27, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced its participation in the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 5, 2024. Stephen Uden, M.D., Chief... Read More

On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024 $88.6 Million in Cash, Cash Equivalents, and Marketable Securities as of June 30, 2024 Provides Runway into Mid-2026 NEW HAVEN, Conn. / Aug 08, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for... Read More

NEW HAVEN, Conn. / Jul 09, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Jonathan Lieber, Chief Financial Officer of Rallybio, will present a corporate overview at the 2024 Jones Healthcare Seaside Summit on July 15, 2024 at 8:00 a.m. PT (11:00... Read More

First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk for FNAIT Annually and the RLYB212 Addressable Market Rallybio On Track to Initiate RLYB212 Phase 2 Dose Confirmation Study in Pregnant Women at Higher Risk for FNAIT in 2H 2024 NEW HAVEN, Conn. / Jun 17, 2024 / Business Wire / Rallybio... Read More

On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2024; Provides Runway into Mid-2026 NEW HAVEN, Conn. / May 09, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for... Read More

NEW HAVEN, Conn. / May 07, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday,... Read More

Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women Among HPA-1a Negative Pregnant Women, Approximately 33% are at Higher Risk for Alloimmunization NEW HAVEN, Conn. / Apr 17, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with... Read More

Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson & Johnson NEW HAVEN, Conn. / Apr 10, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a collaboration with Johnson & Johnson 1 to... Read More

NEW HAVEN, Conn. / Apr 01, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that data from a systematic literature review assessing the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk among pregnant... Read More

Received Protocol Assistance Feedback from European Medicines Agency on the Phase 2 Study for RLYB212; Company to Proceed Forward with Clinical Trial Application Process in Europe Phase 2 Dose Confirmation Study for RLYB212 in Pregnant Women at Higher Risk for FNAIT Expected to Initiate in 2H 2024 $109.9 million Cash, Cash Equivalents and Marketable Securities as of December 31, 2023; Provides Runway into Mid-2026 NEW HAVEN,... Read More

NEW HAVEN, Conn. / Feb 26, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Orphan Bone & Neuromuscular Diseases,” at the TD... Read More

Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement-mediated diseases Anticipated cost savings, including a 45% workforce reduction, extends cash runway into mid-2026 NEW HAVEN, Conn. / Feb 06, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a... Read More

Phase 2 Study for RLYB212 Expected to Initiate in 2H 2024 Company to Provide Update on Phase 2 Discussions with European Medicines Agency for RLYB212 in 1H 2024 Cash Runway Extended into 3Q 2025 NEW HAVEN, Conn. / Jan 04, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with... Read More

100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization Conference Call and Webcast Today at 8:30 AM Eastern Time NEW HAVEN, Conn. / Dec 20, 2023 / Business... Read More

FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women Study Designed to Provide a Contemporary Control Dataset to Support a Future Registrational Trial in Pregnant Women NEW HAVEN, Conn. / Dec 09, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of... Read More

Preliminary Data Support RLYB212 Once Monthly Subcutaneous Dosing in Phase 2 Study RLYB212 Toxicology Package Complete, Including Maternal-Fetal Toxicology; Key Activity to Support Phase 2 and Phase 3 Studies in Pregnant Women RLYB212 Phase 2 Study Expected To Commence in 2H 2024 NEW HAVEN, Conn. / Nov 28, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced preliminary data from the completed multiple... Read More

RLYB212 Phase 1 Multiple Dose Cohort Complete and on Track for 4Q 2023 Data Release Initial Data from RLYB116 Phase 1 Multiple Ascending Dose Study Including Safety, PK and PD on Track for 4Q 2023 Release $121.4 million cash, cash equivalents and marketable securities as of September 30, 2023; Provides Runway into 1Q 2025 NEW HAVEN, Conn. / Nov 09, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today reported... Read More

NEW HAVEN, Conn. / Nov 08, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: Stifel 2023 Healthcare Conference in New York, NY on Wednesday, November 15, 2023.... Read More

NEW HAVEN, Conn. / Nov 02, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, which will be held December 9-12, 2023, in San Diego, California. Details of the poster... Read More

NEW HAVEN, Conn. / Oct 03, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Novel Platform Technologies in Rare Disease and... Read More

First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants Mean Estimated Elimination Half-Life for RLYB116 was > 300 Hours No Severe or Serious Adverse Events with Single-Dose Administration of RLYB116 Phase 1 Multiple Ascending Dose Study of RLYB116 Ongoing;... Read More

NEW HAVEN, Conn. / Aug 31, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 7, 2023.... Read More

RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31 st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 RLYB212 Phase 1 Multiple Dose Cohort Study Results Expected in 4Q 2023 Initial Data from RLYB116 Phase 1 Multiple Ascending Dose Study Including Safety, PK and PD Expected in 4Q 2023 $137.8 million cash, cash equivalents and marketable securities as of June 30, 2023;... Read More

NEW HAVEN, Conn. / Aug 02, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “When You’re One in a Million – Orphan Drug... Read More

NEW HAVEN, Conn. / Jul 11, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116 has been accepted for presentation as a poster at the 29 th International Complement Workshop (ICW), which will take place in Newcastle, UK from August 31 - September 5. RLYB116 is a novel, potentially... Read More

Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman NEW HAVEN, Conn. / Jun 29, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio’s President,... Read More

RLYB212 Demonstrated Dose-Dependent, Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects Mean Reduction in Platelet Elimination Half-Life After Subcutaneous Administration of RLYB212 was ≥90% in both RLYB212 Dose Groups, Achieving Proof-of-Concept Criteria Phase 2 Study in Pregnant Women at Higher Risk of HPA-1a Alloimmunization to be Initiated in 2H 2024 Phase 1 Multiple Dose... Read More

Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH Company to Host Webcast Following ISTH Oral Presentation of RLYB212 NEW HAVEN, Conn. / Jun 09, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,... Read More

NEW HAVEN, Conn. / Jun 01, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9 at 9:00AM ET in New York, NY. A live... Read More

RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31 st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 Phase 1 Multiple Dose Cohort RLYB212 Study Initiated in 1Q 2023; Data Expected in 4Q 2023 Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 $150.4 million cash, cash equivalents and marketable... Read More

NEW HAVEN, Conn. / May 08, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference on Monday, May 15 at 2:30 p.m. ET in New... Read More

Data Support Potential Use of an Anti-HPA-1a Antibody as Prophylaxis for FNAIT In March 2023, Rallybio Announced Clinical Proof-of-Concept Achieved for its Lead Product Candidate, RLYB212, a Monoclonal Anti-HPA-1a Antibody, in the First Quarter of 2023 NEW HAVEN, Conn. / Apr 06, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced publication of Phase 1 / 2 proof-of-concept results for RLYB211, a... Read More

NEW HAVEN, Conn. / Apr 03, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31 st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed... Read More

NEW HAVEN, Conn. / Mar 06, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent program and corporate developments. “In... Read More

NEW HAVEN, Conn. / Mar 06, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Results show that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused,... Read More

NEW HAVEN, Conn. / Mar 01, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: Cowen 43 rd Annual Healthcare Conference in Boston, Massachusetts on Wednesday, March... Read More

NEW HAVEN, Conn. / Jan 31, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company’s Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA,... Read More

Phase 1b Proof-of-Concept Data for RLYB212 on track for 1Q 2023 Initiated Phase 1 Multiple Ascending Dose Study of RLYB116 in 4Q 2022; Safety, PK and PD Data Expected in 2H 2023 Cash Runway Extended into 1Q 2025 following November 2022 Follow-On Offering Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for... Read More

Data Demonstrates that HPA-1a Alloimmunization can be Prevented with Prophylactic Administration of Low Levels of HPA-1a-specific Antibodies NEW HAVEN, Conn.--( BUSINESS WIRE )-- Rallybio Corporation (Nasdaq: RLYB) today announced publication of preclinical study results for two human HPA-1a-specific antibodies in development for the prevention of FNAIT. The results demonstrate that low doses of the two HPA-1a-specific... Read More

AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera’s antibody discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and... Read More

Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). These data demonstrate that one week after a single subcutaneous dose, RLYB212 was able to eliminate transfused HPA-1a positive platelets rapidly compared to placebo in a... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments. “We continue to progress our pipeline toward planned upcoming milestones.... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors. “Wendy is a tremendous addition to our Board of Directors. Her extensive clinical experience and deep scientific expertise... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer (CFO). Mr. Fryer will continue to serve as Rallybio’s CFO until a new CFO has been appointed and will retire from the... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022 at 10:30 a.m. ET. JMP Securities Life Sciences Conference in... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent program and corporate developments. “We continue to move forward with our mission of discovering, developing,... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has obtained worldwide exclusive rights to Sanofi’s KY1066, which will be referred to as RLYB331 going forward, a preclinical potentially first-in-class antibody. RLYB331 has the potential to... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Christine Nash, MBA and Hui Liu, Ph.D., to its Board of Directors. In addition, Tim Shannon, M.D. notified the company that he will resign from the Board, effective at Rallybio’s... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent corporate developments. “Following our successful initial public offering in August 2021, we... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “ Neuromuscular” at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:10... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Ami Bavishi has joined as the company’s Head of Investor Relations and Corporate Communications. Ms. Bavishi brings more than 10 years of experience to Rallybio and will be responsible for... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today provided an update on recent accomplishments and announced expected upcoming milestones. The Company will present these updates at the 40 th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced data from its ongoing Phase 1/2 study of RLYB211 showing significant benefit over placebo. RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, is being evaluated for the prevention of Fetal and... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 8:00 a.m. ET. Rallybio will also host one-on-one... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a pre-recorded fireside chat at the Jefferies London Healthcare Conference. Rallybio will also host one-on-one meetings on Thursday, November 18, 2021. The... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent corporate developments. “We continue to work with unwavering commitment to deliver transformative impact... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate developments. “Since our founding in 2018, Rallybio has made consistent progress towards... Read More

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the closing of its initial public offering of 7,130,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 930,000 additional shares of common... Read More